scholarly journals Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification

2018 ◽  
Vol 35 (6) ◽  
pp. 694-706
Author(s):  
M. E. Trautmann ◽  
J. Vora
Keyword(s):  
Basal Insulin ◽  
Treatment Intensification ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know

2018 ◽  
Vol 36 (2) ◽  
pp. 174-182 ◽  
Author(s):  
Neil Skolnik ◽  
Debbie Hinnen ◽  
Yan Kiriakov ◽  
Melissa L. Magwire ◽  
John R. White
Keyword(s):  
Basal Insulin ◽  
Fixed Ratio ◽  
Insulin Analogs ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes

2010 ◽  
Vol 9 (2) ◽  
pp. 76 ◽  
Author(s):  
Josep Vidal ◽  
Keyword(s):  
Type 2 Diabetes ◽  
Glycaemic Control ◽  
Basal Insulin ◽  
Glycated Haemoglobin ◽  
Insulin Analogues ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Long Acting

Optimal glycaemic control is essential to managing risks in patients with type 2 diabetes. However, glycaemic control remains poor among type 2 diabetes patients, particularly the control of post-prandial glucose (PPG). Almost half of patients treated with basal insulin and oral anti-diabetic drugs (OADs) do not achieve their glycated haemoglobin (HbA1c) goals, despite achieving fasting plasma glucose (FPG) control. Glycaemic control targets have emphasised FPG targets, but PPG contributes significantly to overall glycaemic control in type 2 diabetes. Glucagon-like peptide 1 (GLP-1) receptor agonists have shown substantial efficacy in improving overall glycaemic control but have differing effects on PPG, which is a result of their different mechanisms of action. Lixisenatide is unique among existing GLP-1 receptor agonists in that it is short acting but given as a once daily dose, and exerts its main effects during the prandial period. It has demonstrated efficacy in an extensive clinical trial programme. In particular, it has shown a beneficial effect on PPG compared with existing GLP-1 receptor agonists, probably a result of its effect on slowing gastric emptying. This has provided a strong rationale for its use as add-on therapy to long-acting basal insulin analogues, in cases where the latter is not providing adequate glycaemic control. The additive effects on glycaemic control may lead to a new treatment approach to manage blood glucose and prevent long-term complications in patients with type 2 diabetes.

scholarly journals Real‐world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon‐like peptide‐1 receptor agonists

2020 ◽  
Vol 22 (12) ◽  
pp. 2295-2304
Author(s):  
Julio Rosenstock ◽  
Francisco Javier Ampudia‐Blasco ◽  
Robert Lubwama ◽  
Xuejun Victor Peng ◽  
Anders Boss ◽  
...  
Keyword(s):  
Glycaemic Control ◽  
Real World ◽  
Basal Insulin ◽  
Receptor Agonists ◽  
Real World Evidence ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Combined Insulin and GLP-1 Receptor Agonists: Simplifying Treatment or Adding Obstacles?

2018 ◽  
Vol 32 (4) ◽  
pp. 447-449
Author(s):  
Tianrui Yang ◽  
B. Tate Cutshall ◽  
Alexandra Tatara ◽  
Melanie Ruegger
Keyword(s):  
Insulin Glargine ◽  
Basal Insulin ◽  
Outpatient Setting ◽  
Insulin Degludec ◽  
Transitions Of Care ◽  
Discharge Process ◽  
Receptor Agonists ◽  
The Us ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

The US Food and Drug Administration recently approved 2 combination products containing a basal insulin and a glucagon-like peptide 1 receptor agonist: insulin glargine/lixisenatide and insulin degludec/liraglutide. These agents were shown to be noninferior in lowering hemoglobin A1c compared to basal insulin and are indicated for patients inadequately controlled on basal insulin or glucagon-like peptide 1 receptor agonists alone. The clinical implications of these agents are unclear due to limitations in the clinical trials and limited recommendations in current guidelines. While these agents may provide financial and adherence benefits, their role is likely limited to the outpatient setting. With the availability of these agents, concerns with transitions of care arise due to multiple vulnerabilities in reconciling these agents throughout the inpatient admission and discharge process. Provider awareness of the availability and dosing of insulin glargine/lixisenatide and insulin degludec/liraglutide is essential to reduce errors in the medication reconciliation process.

Sign in / Sign up

Export Citation Format

Share Document